Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Original investigation

Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic type 2 diabetes patients

Authors: Martin Magnusson, Stefan Jovinge, Kambiz Shahgaldi, Bo Israelsson, Leif Groop, Olle Melander

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Background

The aims of this study were to estimate the prevalence of left ventricular systolic (LVSD) and diastolic (LVDD) dysfunction, and to test if BNP and urinary albumin excretion rate (AER) are related to LVSD, LVD and left ventricular mass (LVM) in asymptomatic type 2 diabetes patients.

Methods

Presence of LVSD, LVDD and LVM, determined with echocardiography, was related to levels of BNP and AER in 153 consecutive asymptomatic patients with type 2 diabetes.

Results

LVSD was present in 6.1% of patients whereas 49% (29% mild, 19% moderate and 0.7% severe) had LVDD and 9.4% had left ventricular hypertrophy. Increasing age (P < 0.0001) was the only independent variable related to mild LVDD whereas increasing BNP (P = 0.01), systolic blood pressure (P = 0.01), age (P = 0.003) and female gender (P = 0.04) were independent determinants of moderate to severe LVDD. AER (P = 0.003), age (P = 0.01) and male gender (P = 0.006) were directly and independently related to LVM.

Conclusion

About half of asymptomatic type 2 diabetes patients have LVDD. Of those, more than one third display moderate LVDD pattern paralleled by increases in BNP, suggesting markedly increased risk of heart failure, especially in females, whereas AER and male sex are related to LVM.
Appendix
Available only for authorised users
Literature
1.
go back to reference King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998, 21 (9): 1414-1431. 10.2337/diacare.21.9.1414.CrossRefPubMed King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998, 21 (9): 1414-1431. 10.2337/diacare.21.9.1414.CrossRefPubMed
2.
go back to reference Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002, 359 (9324): 2140-2144. 10.1016/S0140-6736(02)09089-X.CrossRefPubMed Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002, 359 (9324): 2140-2144. 10.1016/S0140-6736(02)09089-X.CrossRefPubMed
3.
go back to reference Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. Jama. 1999, 281 (14): 1291-1297. 10.1001/jama.281.14.1291.CrossRefPubMed Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. Jama. 1999, 281 (14): 1291-1297. 10.1001/jama.281.14.1291.CrossRefPubMed
4.
go back to reference Kostis JB: The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens. 1995, 8 (9): 909-914. 10.1016/0895-7061(95)00156-J.CrossRefPubMed Kostis JB: The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens. 1995, 8 (9): 909-914. 10.1016/0895-7061(95)00156-J.CrossRefPubMed
5.
go back to reference Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002, 359 (9311): 1004-1010. 10.1016/S0140-6736(02)08090-X.CrossRefPubMed Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002, 359 (9311): 1004-1010. 10.1016/S0140-6736(02)08090-X.CrossRefPubMed
6.
go back to reference Gimeno-Orna JA, Molinero-Herguedas E, Sanchez-Vano R, Lou-Arnal LM, Boned-Juliani B, Castro-Alonso FJ: Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes. Diabetes Res Clin Pract. 2006, 74 (1): 103-109. 10.1016/j.diabres.2006.03.008.CrossRefPubMed Gimeno-Orna JA, Molinero-Herguedas E, Sanchez-Vano R, Lou-Arnal LM, Boned-Juliani B, Castro-Alonso FJ: Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes. Diabetes Res Clin Pract. 2006, 74 (1): 103-109. 10.1016/j.diabres.2006.03.008.CrossRefPubMed
7.
go back to reference Struthers AD, Morris AD: Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet. 2002, 359 (9315): 1430-1432. 10.1016/S0140-6736(02)08358-7.CrossRefPubMed Struthers AD, Morris AD: Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet. 2002, 359 (9315): 1430-1432. 10.1016/S0140-6736(02)08358-7.CrossRefPubMed
8.
go back to reference Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S: Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care. 2004, 27 (8): 1929-1935. 10.2337/diacare.27.8.1929.CrossRefPubMed Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S: Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care. 2004, 27 (8): 1929-1935. 10.2337/diacare.27.8.1929.CrossRefPubMed
9.
go back to reference Isaaz K, Thompson A, Ethevenot G, Cloez JL, Brembilla B, Pernot C: Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol. 1989, 64 (1): 66-75. 10.1016/0002-9149(89)90655-3.CrossRefPubMed Isaaz K, Thompson A, Ethevenot G, Cloez JL, Brembilla B, Pernot C: Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol. 1989, 64 (1): 66-75. 10.1016/0002-9149(89)90655-3.CrossRefPubMed
10.
go back to reference Miyatake K, Yamagishi M, Tanaka N, Uematsu M, Yamazaki N, Mine Y, Sano A, Hirama M: New method for evaluating left ventricular wall motion by color-coded tissue Doppler imaging: in vitro and in vivo studies. J Am Coll Cardiol. 1995, 25 (3): 717-724. 10.1016/0735-1097(94)00421-L.CrossRefPubMed Miyatake K, Yamagishi M, Tanaka N, Uematsu M, Yamazaki N, Mine Y, Sano A, Hirama M: New method for evaluating left ventricular wall motion by color-coded tissue Doppler imaging: in vitro and in vivo studies. J Am Coll Cardiol. 1995, 25 (3): 717-724. 10.1016/0735-1097(94)00421-L.CrossRefPubMed
11.
go back to reference Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, et al: Recommendations for chamber quantification. Eur J Echocardiogr. 2006, 7 (2): 79-108. 10.1016/j.euje.2005.12.014.CrossRefPubMed Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, et al: Recommendations for chamber quantification. Eur J Echocardiogr. 2006, 7 (2): 79-108. 10.1016/j.euje.2005.12.014.CrossRefPubMed
12.
go back to reference Bonow RO, Carabello BA, Kanu C, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, et al: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006, 114 (5): e84-231. 10.1161/CIRCULATIONAHA.106.176857.CrossRefPubMed Bonow RO, Carabello BA, Kanu C, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, et al: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006, 114 (5): e84-231. 10.1161/CIRCULATIONAHA.106.176857.CrossRefPubMed
13.
go back to reference Paulus Walter J, Tschope C, Sanderson John E, Rusconi C, Flachskampf Frank A, Rademakers Frank E, Marino P, Smiseth Otto A, De Keulenaer G, Leite-Moreira Adelino F, et al: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European heart journal. 2007, 28 (20): 2539-10.1093/eurheartj/ehm037.CrossRefPubMed Paulus Walter J, Tschope C, Sanderson John E, Rusconi C, Flachskampf Frank A, Rademakers Frank E, Marino P, Smiseth Otto A, De Keulenaer G, Leite-Moreira Adelino F, et al: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European heart journal. 2007, 28 (20): 2539-10.1093/eurheartj/ehm037.CrossRefPubMed
14.
go back to reference Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care. 2001, 24 (1): 5-10. 10.2337/diacare.24.1.5.CrossRefPubMed Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care. 2001, 24 (1): 5-10. 10.2337/diacare.24.1.5.CrossRefPubMed
15.
go back to reference Srivastava PM, Calafiore P, Macisaac RJ, Patel SK, Thomas MC, Jerums G, Burrell LM: Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. Clin Sci (Lond). 2008, 114 (4): 313-320. 10.1042/CS20070261.CrossRef Srivastava PM, Calafiore P, Macisaac RJ, Patel SK, Thomas MC, Jerums G, Burrell LM: Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. Clin Sci (Lond). 2008, 114 (4): 313-320. 10.1042/CS20070261.CrossRef
16.
go back to reference Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J: Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 2001, 310 (2): 193-197. 10.1016/S0009-8981(01)00578-2.CrossRefPubMed Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J: Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 2001, 310 (2): 193-197. 10.1016/S0009-8981(01)00578-2.CrossRefPubMed
17.
go back to reference Lukowicz TV, Fischer M, Hense HW, Doring A, Stritzke J, Riegger G, Schunkert H, Luchner A: BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy. Eur J Heart Fail. 2005, 7 (4): 525-531. 10.1016/j.ejheart.2004.12.010.CrossRefPubMed Lukowicz TV, Fischer M, Hense HW, Doring A, Stritzke J, Riegger G, Schunkert H, Luchner A: BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy. Eur J Heart Fail. 2005, 7 (4): 525-531. 10.1016/j.ejheart.2004.12.010.CrossRefPubMed
18.
go back to reference Nakamura M, Tanaka F, Yonezawa S, Satou K, Nagano M, Hiramori K: The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens. 2003, 16 (12): 1025-1029. 10.1016/j.amjhyper.2003.07.024.CrossRefPubMed Nakamura M, Tanaka F, Yonezawa S, Satou K, Nagano M, Hiramori K: The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens. 2003, 16 (12): 1025-1029. 10.1016/j.amjhyper.2003.07.024.CrossRefPubMed
19.
go back to reference Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001, 141 (3): 334-341. 10.1067/mhj.2001.113218.CrossRefPubMed Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001, 141 (3): 334-341. 10.1067/mhj.2001.113218.CrossRefPubMed
20.
go back to reference Conrady AO, Zaharov DV, Krutikov AN, Vahrameeva NV, Yakovleva OI, Alexeeva NP, Shlyakhto EV, Rudomanov OG: Prevalence and determinants of left ventricular hypertrophy and remodelling patterns in hypertensive patients: the St. Petersburg study. Blood Pressure. 2004, 13 (2): 101-10.1080/08037050410031855.CrossRefPubMed Conrady AO, Zaharov DV, Krutikov AN, Vahrameeva NV, Yakovleva OI, Alexeeva NP, Shlyakhto EV, Rudomanov OG: Prevalence and determinants of left ventricular hypertrophy and remodelling patterns in hypertensive patients: the St. Petersburg study. Blood Pressure. 2004, 13 (2): 101-10.1080/08037050410031855.CrossRefPubMed
21.
go back to reference Schirmer H, Lunde P, Rasmussen K: Prevalence of left ventricular hypertrophy in a general population; The Tromso Study. Eur Heart J. 1999, 20 (6): 429-438. 10.1053/euhj.1998.1314.CrossRefPubMed Schirmer H, Lunde P, Rasmussen K: Prevalence of left ventricular hypertrophy in a general population; The Tromso Study. Eur Heart J. 1999, 20 (6): 429-438. 10.1053/euhj.1998.1314.CrossRefPubMed
22.
go back to reference Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. Jama. 1979, 241 (19): 2035-2038. 10.1001/jama.241.19.2035.CrossRefPubMed Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. Jama. 1979, 241 (19): 2035-2038. 10.1001/jama.241.19.2035.CrossRefPubMed
23.
go back to reference Sanderson JE, Wang M, Yu CM: Tissue Doppler imaging for predicting outcome in patients with cardiovascular disease. Curr Opin Cardiol. 2004, 19 (5): 458-463. 10.1097/01.hco.0000133110.58863.52.CrossRefPubMed Sanderson JE, Wang M, Yu CM: Tissue Doppler imaging for predicting outcome in patients with cardiovascular disease. Curr Opin Cardiol. 2004, 19 (5): 458-463. 10.1097/01.hco.0000133110.58863.52.CrossRefPubMed
24.
go back to reference Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358 (6): 580-591. 10.1056/NEJMoa0706245.CrossRefPubMed Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358 (6): 580-591. 10.1056/NEJMoa0706245.CrossRefPubMed
25.
go back to reference Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, et al: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007, 370 (9590): 829-840. 10.1016/S0140-6736(07)61303-8.CrossRefPubMed Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, et al: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007, 370 (9590): 829-840. 10.1016/S0140-6736(07)61303-8.CrossRefPubMed
Metadata
Title
Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic type 2 diabetes patients
Authors
Martin Magnusson
Stefan Jovinge
Kambiz Shahgaldi
Bo Israelsson
Leif Groop
Olle Melander
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-2

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue